Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy

Inclusion Criteria: * Patients aged 20 or older at the time of writing the informed consent * H. pylori-positive patient. * Patients who are diagnosed with gastric ulcer by endoscopy and have the following ulcer characteristics; Non-scarring ulcer (stage A1, A2, H1, H2 according to the Sakita-Miwa classification), Single ulcer, Ulcer size of 5 to 20mm in diameter Exclusion Criteria: * Patients who previously underwent H. pylori eradication therapy * Malignant gastric ulcer * Linear ulcer * Patients with history of upper GI tract resection or vagotomy * Patients with continuous NSAIDs use within 4 weeks prior to study initiation * Patients with ulcer complications including perforation or pyloric stenosis * Gastric ulcer prone to bleeding (e.g. exposed blood vessels at ulcer base) * Patients with infectious mononucleosis * Patients with known hypersensitivity to penicillin, clarithromycin, omeprazole, amoxicillin or rebamipide * Patients on medications such as terfenadine or pimozide which are contraindicated with clarithromycin usage * Pregnant or possibly pregnant women, lactating women, or those with a plan to conceive during this study * Blood test results of Hb ≤ 8.0 g/dl, platelet ≤50,000 /㎕, total WBC ≤ 4000/㎕ or ≥ 10,000/㎕, and with serum test results showing the levels of AST, ALT, ALP, LDH, BUN, and creatinine exceeding twice the normal range of respective institution. * Other patients deemed not eligible for this study by investigators